Bionovo publishes discoveries in predictable tissue selectivity for selective estrogen receptor modulators platform
Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period
Full Post: Epeius Biotechnologies announces results of Rexin-G in chem-resistant metastatic soft tissue sarcoma and osteosarcoma
Bionovo, Inc. has announced results describing predictable estrogen regulatory elements that can be used to identify estrogenic drugs that are safer.
The data, published in Molecular and Cellular Endocrinology, showed that the new regulatory elements can distinguish the estrogenic pharmacological activity exerted by different compounds and allow for more accurate prediction of specific tissue effect.
“Selective estrogen modulators (SERMs) are an exciting class of drugs that are used to prevent breast cancer and osteoporosis and differ from estrogens in how they regulate gene transcription,” said Dr. Dale Leitman, from the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco. “This study identified gene elements that are activated by SERMs but not by estrogens used in hormone therapy. The identification of these elements, coupled with the understanding of the differential regulation in various tissues by each estrogen receptor subtype, provides a new platform for the discovery of safer estrogenic drugs with SERM-like profiles to prevent and treat a variety of clinical conditions associated with menopause.”
The study was conducted by investigators at The Center for Reproductive Sciences in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco in collaboration with scientists at Bionovo.
“The discovery of these selective estrogen regulatory elements strengthens our SERM discovery engine,” said Isaac Cohen, Bionovo’s Chairman and Chief Executive Officer. “The advantage of the new array, of specific regulatory elements, is manifest in the pharmacological and toxicological insights gained. We can now acquire higher predictive value and greater specificity from a complex biological system such as the regulation of the estrogen receptor pathways. I believe this puts Bionovo at the forefront of future SERM products which are far more specific and a more favorable safety profile. This is a breakthrough for all future drugs that regulate the vast diverse effects of conditions affected by nuclear receptors. Bionovo is positioned to explore and exploit these pathways for many serious diseases with its expanded scientific collaborations. We are proud to continue pursuing our innovative approaches to drug discovery and development in these challenging times.”
For decades, scientists have been studying nuclear hormone receptors to gain a better understanding of how they turn genes on and off throughout the body and how they function as key drug targets for a number of diseases, such as diabetes, breast cancer, osteoporosis and high cholesterol. A new UVA Health System study, led by
Full Post: Breakthrough reveals first ever complete structure of a nuclear hormone receptor on human DNA
Researchers S. Stanley Young, Ph.D., Assistant Director of the National Institute of Statistical Sciences, Heejung Bang, Ph.D., of Cornell University and Kutluk Oktay. MD, FACOG, Professor of Obstetrics & Gynecology and Director, Division of Reproductive Medicine & Infertility Department of Obstetrics & Gynecology from New York Medical College, wrote a paper, “Cereal-Induced Gender Selection? Most
Full Post: You may not be what your mother eats
The molecular details of Aromatase, the key enzyme required for the body to make estrogen, are no longer a mystery thanks to the structural biology work done by the Ghosh lab at the Hauptman-Woodward Medical Research Institute (HWI) in Buffalo, New York. Dr. Debashis Ghosh’s solution of the three-dimensional structure of aromatase is the first
Full Post: Scientists visualize the mechanism of synthesizing estrogen
An intra cellular pathway not previously linked to breast cancer is driving a sub-type of the disease that is highly lethal and disproportionately over-represented in African American women. The pathway regulates how cells identify and destroy proteins and represents a class of genes called proteasome targeting complexes. The work shows that basal cancer cells degrade
Full Post: Scientists find intra cellular pathway driving a deadly sub-type of breast cancer
New research strengthens the link between water pollution and rising male fertility problems. The study, by Brunel University, the Universities of Exeter and Reading and the Centre for Ecology & Hydrology, shows for the first time how a group of testosterone-blocking chemicals is finding its way into UK rivers, affecting wildlife and potentially humans. The
Full Post: Water pollution linked to male fertility problems